Capricor Therapeutics is a clinical-stage biotechnology company focused on developing innovative cell and exosome-based therapies. The company's R&D pipeline primarily targets the treatment of rare diseases, with a specific focus on advancing the clinical validation and commercialization of drugs for Duchenne muscular dystrophy (DMD).